Abstract
The present study was carried out to evaluate the effect of 1α-hydroxycholecalcif erol (1α-(OH)-D3) on serum free and total calcium, parathyroid hormone, alkaline phosphatase, bone X-P change and renal function in 21 hypocalcemic patients under hemodialysis and 7 non-dialysed patients. 1) 21 hypocalcemic patients under hemodialysis were treated with 1α-(OH)-D3 for 6 months. 1α-(OH)-D3 induced a significant increase in serum calcium concentration after 4 weeks and it reached to normal level after 8 weeks. It also induced a significant reduction of raised serum parathyroid hormone and alkaline phosphatase activity after 16 weeks. No significant changes were obtained in phosphate, creatinine and bone X-P. 2) 7 hypocalcemic non-dialysed patients were also treated by 1α-(OH)-D3 for 4 to 20 weeks against 9 normocalcemic chronic renal failure (control). 1α-(OH)-D3 induced a significant increase in serum calcium and reduction of parathyroid hormone after 16 weeks, It also induced a increase in serum creatinine concentration after 12 weeks which was greater than that of control patients. This result suggests that 1α-(OH)-D3 treatment is noxious to the renal function of chronic renal failure.
